Guangrong Zheng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6274741/publications.pdf

Version: 2024-02-01

102 papers	3,247 citations	185998 28 h-index	174990 52 g-index
103 all docs	103 docs citations	103 times ranked	2990 citing authors

#	Article	IF	Citations
1	A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nature Medicine, 2019, 25, 1938-1947.	15.2	348
2	Discovery of piperlongumine as a potential novel lead for the development of senolytic agents. Aging, 2016, 8, 2915-2926.	1.4	188
3	Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy. Journal of the National Cancer Institute, 2021, 113, 1285-1298.	3.0	156
4	Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nature Communications, 2020, 11, 1996.	5.8	141
5	PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics. Oncogene, 2020, 39, 4909-4924.	2.6	139
6	Vesicular monoamine transporter 2: Role as a novel target for drug development. AAPS Journal, 2006, 8, E682-E692.	2.2	104
7	The curcumin analog EF24 is a novel senolytic agent. Aging, 2019, 11, 771-782.	1.4	100
8	Oxidation resistance 1 is a novel senolytic target. Aging Cell, 2018, 17, e12780.	3.0	95
9	Extending the analysis of nicotinic receptor antagonists with the study of Î±6 nicotinic receptor subunit chimeras. Neuropharmacology, 2008, 54, 1189-1200.	2.0	82
10	Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies. Journal of Hematology and Oncology, 2020, 13, 103.	6.9	69
11	Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs. Chemical Communications, 2020, 56, 9866-9869.	2.2	68
12	Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. European Journal of Medicinal Chemistry, 2020, 192, 112186.	2.6	68
13	Cellular senescence and radiation-induced pulmonary fibrosis. Translational Research, 2019, 209, 14-21.	2.2	66
14	DT2216â€"a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. Journal of Hematology and Oncology, 2020, 13, 95.	6.9	64
15	Lobeline Analogs with Enhanced Affinity and Selectivity for Plasmalemma and Vesicular Monoamine Transporters. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 1035-1045.	1.3	63
16	Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity. Aging Cell, 2020, 19, e13117.	3.0	60
17	Defunctionalized Lobeline Analogues:Â Structureâ"Activity of Novel Ligands for the Vesicular Monoamine Transporter. Journal of Medicinal Chemistry, 2005, 48, 5551-5560.	2.9	59
18	Stereoselective Total Synthesis of (3R,8S)-Falcarindiol, a Common Polyacetylenic Compound from Umbellifers. Journal of Natural Products, 1999, 62, 626-628.	1.5	57

#	Article	IF	Citations
19	Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,. Nature Communications, 2021, 12, 6896.	5.8	56
20	Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X_L. Chemical Communications, 2019, 55, 14765-14768.	2.2	54
21	Lobelane Inhibits Methamphetamine-Evoked Dopamine Release via Inhibition of the Vesicular Monoamine Transporter-2. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 612-621.	1.3	45
22	Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation. Bioorganic and Medicinal Chemistry, 2018, 26, 3925-3938.	1.4	42
23	Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. European Journal of Medicinal Chemistry, 2020, 199, 112397.	2.6	38
24	Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. Bioorganic and Medicinal Chemistry, 2005, 13, 3899-3909.	1.4	35
25	Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nature Communications, 2021, 12, 1281.	5.8	34
26	Structural Modifications to Tetrahydropyridine-3-carboxylate Esters en Route to the Discovery of M5-Preferring Muscarinic Receptor Orthosteric Antagonists. Journal of Medicinal Chemistry, 2013, 56, 1693-1703.	2.9	33
27	Overcoming Cancer Drug Resistance Utilizing PROTAC Technology. Frontiers in Cell and Developmental Biology, 2022, 10, 872729.	1.8	32
28	Absolute configuration of falcarinol, a potent antitumor agent commonly occurring in plants. Tetrahedron Letters, 1999, 40, 2181-2182.	0.7	31
29	Discovery of non-peptide, small molecule antagonists of Î±9Î±10 nicotinic acetylcholine receptors as novel analgesics for the treatment of neuropathic and tonic inflammatory pain. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 2476-2479.	1.0	29
30	Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin. Journal of Medicinal Chemistry, 2017, 60, 9630-9640.	2.9	29
31	Assays and technologies for developing proteolysis targeting chimera degraders. Future Medicinal Chemistry, 2020, 12, 1155-1179.	1.1	29
32	Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XLâ€“Specific Degrader DT2216. Molecular Cancer Therapeutics, 2022, 21, 184-192.	1.9	29
33	First total synthesis of optically active panaxydol, a potential antitumor agent isolated from Panax ginseng. Tetrahedron Letters, 1998, 39, 9521-9522.	0.7	28
34	Indirect Trapping of the Retroconjugate Addition Reaction Intermediate Involved in the Epimerization of Lobeline:Â Application to the Synthesis of (âˆ')-Sedamine. Journal of Organic Chemistry, 2004, 69, 8514-8517.	1.7	28
35	Discovery of a Novel BCL-X_L PROTAC Degrader with Enhanced BCL-2 Inhibition. Journal of Medicinal Chemistry, 2021, 64, 14230-14246.	2.9	28
36	Computational neural network analysis of the affinity of lobeline and tetrabenazine analogs for the vesicular monoamine transporter-2. Bioorganic and Medicinal Chemistry, 2007, 15, 2975-2992.	1.4	27

#	Article	IF	Citations
37	Synthesis and evaluation of a series of homologues of lobelane at the vesicular monoamine transporter-2. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 6509-6512.	1.0	27
38	The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats. Psychopharmacology, 2012, 220, 395-403.	1.5	27
39	BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. Journal of Hematology and Oncology, 2022, 15, 23.	6.9	25
40	Syntheses of two diastereoisomers of panaxytriol, a potent antitumor agent isolated from panax ginseng. Tetrahedron, 1999, 55, 7157-7168.	1.0	24
41	Targeting anti-apoptotic BCL-2 family proteins for cancer treatment. Future Medicinal Chemistry, 2020, 12, 563-565.	1.1	22
42	Selective Inhibition of Acetylcholine-Evoked Responses of Î±7 Neuronal Nicotinic Acetylcholine Receptors by Novel tris- and tetrakis-Azaaromatic Quaternary Ammonium Antagonists. Molecular Pharmacology, 2009, 76, 652-666.	1.0	21
43	Molecular Dynamics Guided Design of Tocoflexol: A New Radioprotectant Tocotrienol with Enhanced Bioavailability. Drug Development Research, 2014, 75, 10-22.	1.4	21
44	Novel N-1,2-Dihydroxypropyl Analogs of Lobelane Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-Evoked Dopamine Release. Journal of Pharmacology and Experimental Therapeutics, 2011, 339, 286-297.	1.3	19
45	New histone demethylase LSD1 inhibitor selectively targets teratocarcinoma and embryonic carcinoma cells. Bioorganic and Medicinal Chemistry, 2018, 26, 1523-1537.	1.4	19
46	Effects of <scp>VMAT</scp>2 inhibitors lobeline and <scp>GZ</scp>â€793A on methamphetamineâ€induced changes in dopamine release, metabolism and synthesis in vivo. Journal of Neurochemistry, 2013, 127, 187-198.	2.1	18
47	Design, Synthesis and Interaction at the Vesicular Monoamine Transporter-2 of Lobeline Analogs: Potential Pharmacotherapies for the Treatment of Psychostimulant Abuse. Current Topics in Medicinal Chemistry, 2011, 11, 1103-1127.	1.0	17
48	Amberlite IR-120H as an efficient and versatile solid phase catalyst for nucleophilic substitution of propargylic alcohols. Tetrahedron Letters, 2013, 54, 3550-3553.	0.7	17
49	First Total Synthesis of Panaxytriol, a Potent Antitumor Agent Isolated from Panax Ginseng. Synlett, 1998, 1998, 737-738.	1.0	16
50	A mild and efficient AgSbF6-catalyzed synthesis of fully substituted pyrroles through a sequential propargylation/amination/cycloisomerization reaction. Tetrahedron, 2014, 70, 5267-5273.	1.0	16
51	AgSbF6-catalyzed efficient propargylation/cycloisomerization tandem reaction for the synthesis of fully substituted furans and new insights into the reaction mechanism. Tetrahedron, 2015, 71, 6183-6188.	1.0	16
52	r-bPiDI, an Î±6Î²2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research, 2015, 40, 2121-2130.	1.6	16
53	Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4463-4466.	1.0	15
54	Syntheses of two enantiomers of eicos-(4E)-en-1-yn-3-ol, a bioactive component of the marine sponge Cribrochalina vasculum. Tetrahedron, 1999, 55, 4649-4654.	1.0	14

#	Article	IF	Citations
55	The characterization of a novel rigid nicotine analog with Î±7-selective nAChR agonist activity and modulation of agonist properties by boron inclusion. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3874-3880.	1.0	14
56	tris-Azaaromatic quaternary ammonium salts: Novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6701-6706.	1.0	14
57	Microscopic Binding of M5 Muscarinic Acetylcholine Receptor with Antagonists by Homology Modeling, Molecular Docking, and Molecular Dynamics Simulation. Journal of Physical Chemistry B, 2012, 116, 532-541.	1.2	14
58	Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats. Pharmacology Biochemistry and Behavior, 2013, 112, 29-33.	1.3	14
59	Repeated nicotine administration robustly increases bPiDDB inhibitory potency at Î±6Î²2-containing nicotinic receptors mediating nicotine-evoked dopamine release. Biochemical Pharmacology, 2010, 80, 402-409.	2.0	13
60	The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats. Psychopharmacology, 2012, 224, 255-262.	1.5	13
61	PROTACs are effective in addressing the platelet toxicity associated with BCL-XL inhibitors. Exploration of Targeted Anti-tumor Therapy, 2020, 1, 259-272.	0.5	13
62	Bis-azaaromatic quaternary ammonium salts as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release: An investigation of binding conformation. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6734-6738.	1.0	12
63	Tetrakis-azaaromatic quaternary ammonium salts: Novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5753-5757.	1.0	12
64	<scp>GZ</scp>â€793A, a lobelane analog, interacts with the vesicular monoamine transporterâ€2 to inhibit the effect of methamphetamine. Journal of Neurochemistry, 2013, 127, 177-186.	2.1	12
65	Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats. Psychopharmacology, 2018, 235, 1439-1453.	1.5	12
66	An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic Î±6Î²2* antagonist r-bPiDI. Drug and Alcohol Dependence, 2018, 193, 154-161.	1.6	12
67	Licochalcone A is a natural selective inhibitor of arginine methyltransferase 6. Biochemical Journal, 2021, 478, 389-406.	1.7	12
68	Bis-azaaromatic quaternary ammonium salts as ligands for the bloodâ€“brain barrier choline transporter. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3208-3210.	1.0	11
69	Asymmetric synthesis of (S)- and (R)-norketamine via Sharpless asymmetric dihydroxylation/Ritter amination sequence. Tetrahedron Letters, 2015, 56, 2608-2610.	0.7	11
70	Des-keto lobeline analogs with increased potency and selectivity at dopamine and serotonin transporters. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5018-5021.	1.0	10
71	Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochemical Pharmacology, 2007, 74, 1271-1282.	2.0	10
72	Phenyl Ring-Substituted Lobelane Analogs: Inhibition of [³H]Dopamine Uptake at the Vesicular Monoamine Transporter-2. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 724-733.	1.3	10

#	Article	IF	Citations
73	Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 88-91.	1.0	9
74	Synthesis of (2 R ,8â€² S ,3â€² E)-Î´-tocodienol, a tocoflexol family member designed to have a superior pharmacokinetic profile compared to Î´-tocotrienol. Tetrahedron, 2016, 72, 4001-4006.	1.0	9
75	GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2. European Journal of Pharmacology, 2017, 795, 143-149.	1.7	9
76	The Preparation of 2â€Arylmethylideneâ€8â€methylâ€8â€azabicyclo[3.2.1]octanâ€3â€ones. Synthetic Communications, 2004, 34, 1931-1942.	1.1	7
77	1,4-Diphenalkylpiperidines: A new scaffold for the design of potent inhibitors of the vesicular monoamine transporter-2. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2997-3000.	1.0	7
78	Deuteration of the farnesyl terminal methyl groups of Î´-tocotrienol and its effects on the metabolic stability and ability of inducing G-CSF production. Bioorganic and Medicinal Chemistry, 2020, 28, 115498.	1.4	7
79	Exploring the effect of N-substitution in nor-lobelane on the interaction with VMAT2: discovery of a potential clinical candidate for treatment of methamphetamine abuse. MedChemComm, 2013, 4, 564.	3.5	6
80	Synthesis of Lobeline, Lobelane and their Analogues. A Review. Organic Preparations and Procedures International, 2015, 47, 317-337.	0.6	6
81	Targeting BCL-XL and BCL-2 By Protac 753B Effectively Eliminates AML Cells and Enhances Efficacy of Chemotherapy By Targeting Senescent Cells. Blood, 2021, 138, 2230-2230.	0.6	6
82	New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders. AAPS Journal, 2018, 20, 29.	2.2	5
83	Synthesis and Liver Microsomal Metabolic Stability Studies of a Fluorineâ€Substituted Î´â€Tocotrienol Derivative. ChemMedChem, 2020, 15, 506-516.	1.6	5
84	Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models. Blood, 2019, 134, 3870-3870.	0.6	5
85	Stereocontrolled Synthesis and Pharmacological Evaluation ofcis-2,6-Diphenethyl-1-azabicyclo[2.2.2]octanes as Lobelane Analogues. Journal of Organic Chemistry, 2009, 74, 6072-6076.	1.7	4
86	GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 526-543.	1.3	4
87	Muscarinic acetylcholine receptor binding affinities of pethidine analogs. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5032-5035.	1.0	3
88	Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [3H]dopamine uptake at the vesicular monoamine transporter-2. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2422-2427.	1.0	3
89	Synthesis and in vitro evaluation of water-soluble 1,4-diphenethylpiperazine analogs as novel inhibitors of the vesicular monoamine transporter-2. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4441-4445.	1.0	3
90	Mitigation of late cardiovascular effects of oxygen ion radiation by Î³-tocotrienol in a mouse model. Life Sciences in Space Research, 2021, 31, 43-50.	1.2	3

#	Article	IF	Citations
91	DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia. Blood, 2019, 134, 303-303.	0.6	3
92	Synthesis of O- and N-alkylated products of 1,2,3,4-tetrahydrobenzo[c][2,7]naphthyrin-5(6H)-one. Tetrahedron Letters, 2015, 56, 6472-6474.	0.7	2
93	Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats. Behavioural Pharmacology, 2018, 29, 87-97.	0.8	2
94	A Facile Semisynthesis and Evaluation of Garcinoic Acid and Its Analogs for the Inhibition of Human DNA Polymerase Î². Molecules, 2020, 25, 5847.	1.7	2
95	Concise Synthesis of (S)-Î´-CEHC, a Metabolite of Vitamin E. ACS Omega, 2021, 6, 4355-4361.	1.6	2
96	Senolytic Drug Development. Healthy Ageing and Longevity, 2020, , 3-20.	0.2	2
97	Two isomers of 2,4-dibenzyl-8-azabicyclo[3.2.1]octan-3-ol. Acta Crystallographica Section C: Crystal Structure Communications, 2004, 60, o9-o11.	0.4	1
98	(S)-1-(2-Chlorophenyl)-2-oxocyclohexan-1-aminiumD-tartrate. Acta Crystallographica Section E: Structure Reports Online, 2011, 67, o736-o736.	0.2	1
99	DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-XL for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax. Blood, 2018, 132, 2698-2698.	0.6	1
100	Muscarinic agonist, (Â±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M1 â€“ M5 muscarinic acetylcholine receptors. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 471-476.	1.0	0
101	Discovery of M5 Muscarinic Acetylcholine Receptor Antagonists: 1â€Methylâ€4â€Phenylpiperidine Analogs. FASEB Journal, 2015, 29, 768.17.	0.2	0
102	Targeting Venetoclax-Resistant CLL By Bcl-XL Degradation. Blood, 2021, 138, 2252-2252.	0.6	0